BTIG affirms Kite Pharma, Inc. (Nasdaq: KITE) with a Neutral rating after the company announced the first patient was enrolled ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Stifel Reiterates Bullish View on Kite Pharma (KITE) Following New Trial NewsOctober 6, 2016 10:12 AM Kite Pharma (KITE) Commences KTE-C19 Combo Phase 1b/2 Combination Study in DLBCL (RHHBY)October 6, 2016 8:31 AM Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL)October 6, 2016 8:30 AM Form 4 Kite Pharma, Inc. For: Oct 03 Filed by: Wiezorek JeffreyOctober 5, 2016 7:44 PM Form CT ORDER Kite Pharma, Inc. October 4, 2016 4:24 PM